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Abstract
In adults, bone is the preferential target site for metastases from primary cancers of prostate, breast, lungs and
thyroid. The tendency of these cancers to metastasize to bone is determined by the anatomical distribution of the
blood vessels, by the genetic profile of the cancer cells and by the biological characteristics of the bone
microenvironment that favour the growth of metastatic cells of certain cancers.
Metastases to bone may have either an osteolytic or an ostoblastic phenotype. The interaction in the bone
microenvironment between biological factors secreted by metastatic cells, and by osteoblasts and osteoclasts, and
the osteolytic and osteoblastic factors released from the organic matrix mediate a vicious cycle characterized by
metastatic growth and by ongoing progressive bone destruction. This interaction determines the phenotype of the
metastatic bone disease.
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Introduction
If primary cancer cells penetrate the walls of blood or
lymphatic vessels and gain access to the blood or lymph
stream, they may spread to remote sites, where depend-
ing upon their interaction with stromal, endothelial and
immune cells in their new microenvironment, they may
either die, or survive in a dormant state, or undergo clo-
nal expansion to form a metastatic growth [1]. It is
probable that those cells that do form a metastatic
growth are cells which possess the cytogenetic profile
conferring upon them the potential to initiate and sus-
tain growth in a favourable microenvironment [2].
The gene profile that conveys the potential for meta-
static growth may be expressed in certain primary can-
cer cells early in carcinogenesis, or may be acquired
only later in the course of primary cancer progression,
as a result of evolution of subclones of cancer cells that
have undergone multiple episodes of cytogenetic and
epigenetic alteration [1-7].
Cells with a cancer stem cell phenotype which disse-
minate early in the course of the primary cancer, often
remain dormant in their new location for a long time,
and become active only if or when their new microen-
vironment favours growth of the metastatic cancer cells.
If the primary cancer is large, it can be not only a
source of metastasizing cells, but also of biologically
active mediators that promote development of favour-
able prematastatic niches, where colonization by dor-
mant or newly-arrived metastatic cells, will be supported
[2,5,6].
Primary cancers of lung, breast, thyroid and prostrate
commonly metastasize to bone, almost invariably by
haematogenous spread [8-11]. The genetic and epige-
netic evolution of metastatic cells of these primary can-
cers, regardless of whether they leave the primary
cancer at an early or at a late stage of its growth, confer
tropism for bone upon these metastasizing cells, and fit-
ness to occupy metastatic niches in bone [1].
Cells of osteotropic cancers express the chemokine
receptor CXCR4 on their surfaces, and respond to che-
moatractant signals generated by its receptor ligand, the
stromal-derived factor-1 (SDF-1) that is secreted in the
bone microenvironment by osteoblasts, fibroblasts, and
by haematopoietic stem/progenitor cells and endothelial
stem/progenitor cells in the bone marrow stroma; and is
strongly expressed in the bone premetastatic niche
[12,13]. The growth of micrometastases is promoted by
interaction with gene products in the bone microenvir-
onment (chemokines, cytokines, growth factors) [1].
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bone
Metastases to bone more frequently affect long bones,
ribs and vertebrae than other parts of the skeleton, most
commonly near the trabecular metaphyses. This pattern
of distribution is influenced by the slower rate of blood
flow in the marrow-rich metaphyses where the increased
sinusoidal blood pressure together with the chemoat-
traction of the chemokine SDF-1 favours adhesion of
the CXCR4+ metastatic cells to the endothelium and
their subsequent extravasation [14]. SDF-1 also mobi-
lises bone marrow-derived haematopoietic progenitor
cells and endothelial progenitor cells to the metastatic
niche [15,16].
Endothelial cells of different candidate metastatic tis-
sues express tissue-specific lectins and integrins that
preferentially bind type-specific metastatic cells [17]. For
example prostate cancer cell adhesion to bone marrow
endothelial cells is mediated by avb3 integrins
[14,15,18]. Extravasation is mediated by proteolytic
enzymes such as matrix metalloproteinase-9 and uroki-
nase plasminogen activator, which promote degradation
of and increased permeability of the basement mem-
brane [17].
Once within the bone-marrow stromal microenviron-
ment, the metastatic cells migrate to the endosteal bone
surfaces where depending on the cancer cell phenotype
they either mediate osteoblastic bone deposition or
osteoclastic bone resorption through molecular interac-
tions with resident cells and with biological agents
[19,20]. It is likely that metastatic cells expressing avb3
integrins bind to bone matrix proteins including col-
lagens, fibronectin, vitronectin and osteopontin, estab-
lishing the growth of the metastasis within the bone
[12]. There is some controversy as to whether the colo-
nizing cells mediate the angiogenesis necessary for their
own proliferation or whether they use the existing bone
marrow vasculature [19].
Classification of bone metastases
In bone, depending upon the phenotype of the cells of
the primary cancer, the colonizing metastatic cells
induce either osteoclast-mediated bone resorption with
the development of osteolytic bone lesions; or osteo-
blast-mediated bone deposition characterized by
increased bone density. In some cases, the development
of mixed osteoblastic/osteolytic lesions is induced. In
metastatic bone lesions of prostate, carcinoid and other
neuroendocrine cancers the osteoblastic phenotype gen-
erally predominates whereas metastases of lung, kidney
and breast cancers are primarily osteolytic [20,21].
Although osteolytic lesions in metastatic bone dis-
ease are brought about by osteoclast mediated bone
resorption, therapeutically blocking the osteoclastic
activity does not lead to reversal of the osteolysis, indi-
cating that impairment of osteoblast function plays
some role in the persistence of osteolytic metastatic
bone disease [22]. It is recognized that osteoblastic
activity associated with metastatic cells also starts with
a phase of abnormal bone resorption, and only later in
the course of the metastatic bone disease is there a
shift to predominantly osteoblastic activity character-
ized by formation of abnormal disorganized bone con-
currently with a marked reduction in osteoclastic
activity [20,23]. Ultimately, the effect of the metastatic
cells on normal bone remodelling, and how the bal-
ance between bone formation and bone resorption is
affected, will define the phenotype of the metastatic
bone disease [24,25].
Regardless of their phenotype, metastatic bone lesions
cause a variety of complications including pain, patholo-
gical fractures, compression of the spinal cord and
hypercalcemia, all of which contribute to increased mor-
bidity and mortality [11,21,26,27]. Once bone metastases
have developed, conservative cure is no longer possible
[20].
Aspects of bone physiology related to metastatic
bone disease
Bone mass is maintained by a balance between osteo-
blast-mediated bone formation and osteoclast-mediated
bone resorption [8]. Osteoblasts originate from bone
marrow stromal progenitor cells; they synthesize and
secrete extracellular organic matrix, and induce the
mineralisation of this matrix. On the other hand osteo-
clasts originate from monocyte/macrophage lineage of
precursor cells in the bone marrow; they resorb bone.
Osteoblast differentiation and maturation is brought
about by activation of specific transcription factors
(RUNX2, osterix) mediated by bone morphogenic pro-
teins and by Wnt signalling pathways [28]. Several pro-
teins essential for bone formation including bone
sialoprotein, osteocalcin, alkaline phosphatase and type
1 collagen, are synthesized by osteoblasts. The function-
ing of osteoblasts is regulated by parathyroid hormone
(PTH); by 1,25 dihydroxyvitamin D [1,25(OH2)D]; and
by growth factors including transforming growth factor
b (TGF b), fibroblast growth factors (FGFs), platelet-
derived growth factor (PDGF) and insulin-like growth
factors (IGFs) [20,29].
Osteoclasts cause bone resorption and their function
is regulated by multiple biological mediators including
parathyroid hormone (PTH), calcitonin, oestrogen, 1,25
(OH2)D, marcrophage colony-stimulating factor (M-
CSF), tumour necrosis factor (TNF), interleukin (IL)-1,
IL-6, IL-11 and interferon g [28-30].
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tion of osteoclasts is critically dependent on the RANK/
RANKL/OPG signalling pathway. Osteoclasts and their
precursor cells express the cell surface-receptor RANK.
On the other hand osteoblasts precursors and other
bone stromal cells express RANK ligand (RANKL), both
as a membrane-bound or as a soluble ligand. They also
express osteoprotegerin (OPG), a soluble decoy receptor
for RANKL [28,31,32].
RANKL binds to RANK on osteoclast progenitor cells
stimulating their differentiation, maturation and activa-
tion, whereas OPG binds to RANK, inhibiting osteoclas-
togenenesis [33]. The balance between the activity of
RANKL, OPG and the biological mediators listed above
determines thus the magnitude of osteoclastogenesis
and the subsequent bone resorption [28,34].
Osteoclast differentiation besides being supported by
RANKL, is also supported by colony stimulating factor-
1 (CSF-1) which is also required for osteoclast survival
[35]. Both cell surface-bound and secreted CSF-1 can
contribute to osteoclast activation. In an in vitro study,
high levels of CSF-1 produced by tumour cells protect
osteoclasts from the suppressive effects of TGF-b and
thus contributed to osteoclast development and survival
in bone metastasis [36].
Osteolytic bone metastasis
Metastases of primary cancers known to cause osteolytic
lesions, specifically breast cancer, secrete biological med-
iators including parathyroid hormone-related protein
(PTHrP), interleukin (IL)-11, IL-8, and IL-6 [19,37],
which induce osteoclast mediated bone resorption
through activation of the RANK/RANKL/OPG signalling
pathway [20]. These mediators upregulate the expres-
sion of RANKL and down regulate the expression of
OPG by osteoblasts and other stromal cells, thus pro-
moting osteoclast differentiation and activation, culmi-
nating in bone resorption.
In turn, growth factors, in particular transforming
growth factor (TGF)-b and insulin growth factors
(IGFs), are released from the organic matrix following
the osteoclast mediated dissolution of the inorganic
crystalline apatite component of bone, further indu-
cing production of PTHrP which is important for the
establishment and progression of osteolytic bone
metastasis [38]. This induces upregulation of IL-11
gene expression and promotes tumour cell prolifera-
tion and survival. Furthermore, these biological factors
provide chemoattractant signals, thus increasing the
fitness of the niche to accommodate additional meta-
static cells.
Thus, the molecular interaction between cancer cells,
stromal cells, and the local ‘fertile’ microenvironment
within the metastatic niche in the bone, creates a
‘vicious cycle’ that favours osteolytic bone destruction
and metastatic growth [2,6,9,19,20,31,37,39].
In addition, certain metastatic cancer cells secrete
matrix metalloproteinases (MMP)-2 and MMP-9 [38], as
well as osteopontin and bone sialoprotein into the local
bone microenvironment. These have the capacity to
alter bone turnover and to promote metastatic growth
[25,40,41].
Interrupting the RANK/RANKL/OPG signalling path-
way by blocking RANKL activity either by OPG or by
RANKL specific antibodies; or by blocking RANK recep-
tors with specific antibodies, may bring about inhibition
of osteoclast differentiation, maturation and functional
activity, resulting in reduced osteoclast-mediated bone
resorption with consequent reduction in metastatic
growth [30,33].
There is another mechanism associated with the
development of osteolytic bone metastases. Primary can-
cer cells which enter the blood-stream, stimulate periph-
eral blood mononuclear cells, particularly T
lymphocytes, to release tumour necrosis factor-a (TNF-
a) which promotes the differentiation of monocytes into
osteoclast precursor cells. These osteoclast precursor
cells are drawn to the metastatic niche in the bone
microenvironment, where they mature and participate
in osteoclastic bone resorption, subsequently mediating
metastatic growth [10].
Osteoblastic bone metastasis
The metastaic cells of primary cancers, in particular
cells of prostate cancer which have the potential to
induce osteoblastic activity, express a number of factors
that mediate bone deposition: platelet derive growth fac-
tor (PDGF), ligands of the Wnt signalling pathway, insu-
lin-like growth factor (IGF), transforming growth factor-
b (TGF-b), bone morphogenic proteins (BMPs), and
fibroblast growth factors (FGFs). These promote osteo-
blast differentiation, proliferation and formation of weak
disorganized woven bone [20,21,25,37]. Osteoblastic
bone metastasis despite its ultimate manifestation, is
preceded or accompanied by osteoclastic activity which
plays an important role in preparing the local environ-
ment favourable of developing an osteoblastic lesion
[21,42].
In the bone microenvironment, BMP-6 promotes
osteoblastogenesis and metastatic growth presumably
through activation of the downstream target gene Id-1
and activation of MMPs [43]; and BMP-6 is associated
with aggressive behaviour of the metastatic bone disease
[23,25].
Prostate metastatic cells also express non-collagenous
matrix proteins including osteocalcin and bone sialopro-
tein, which may enhance bone mineralization, and med-
iate adhesion of osteoclasts and osteoblasts to the
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bone turnover and a net increase in bone formation
[44].
Furthermore, prostate cancer cells express the serine
proteases kallikrein and urokinase-type plasminogen
activator (u-PH) which are mitogenic for osteoblasts;
express the prostate-specific antigen (PSA), another ser-
ine protease, which has the capacity to stimulate osteo-
blast activating factors, IGF-1 and TGF-b;a n da l s o
express the vasoactive peptide endothelin-1 (ET-1) that
is a potent vasoconstrictor, but can also induce osteo-
blast growth [8,20,25,29,31,37].
Prostate cancer cells also produce PTHrP. Although
PTHrP is an osteolytic factor, PSA can cleave PTHrP at
the N-terminal, not only blocking PTHrP-induced bone
resorption, but converting PTHrP to an anabolic stimu-
lant of bone deposition [20,31,37].
The activation of the Wnt canonical pathway in osteo-
blasts results in bone formation and inhibition of bone
resorption [32]. On the other hand, loss of function of
Wnt proteins, or upregulation of DKK1, an inhibitor of
the Wnt canonical pathway results in a net reduction of
bone mass [31,32]. ET-1 which is expressed in bone
osteoblastic lesions, decreases DKK-1 expression leading
to loss of inhibition of Wnt signalling pathways, result-
ing in increased bone formation [37]. Furthermore, cells
of advanced metastatic prostate carcinoma secrete Wnt
ligands, and the Wnt canonical signalling pathway is
activated in osteoblasts within the osteoblastic bone
lesions [8,24].
Treatment of metastatic bone disease
Traditionally, the treatment of cancer metastasis com-
prised chemotherapeutic cytotoxic agents or radiation
which directly targets tumour cells. However, as it is
evident that the development and progression of meta-
static bone disease is driven by complex interactions
between metastatic cancer cells and the bone microen-
vironment, in principle each pathway of these interac-
tions may be an additional potential target for
treatment [45].
Bisphosphonates are synthetic analogues of inorganic
pyrophosphates which target and inhibit cellular
mechanisms of osteoclast-mediated bone resorption,
resulting in suppression of bone-turnover and remodel-
ing. Because of these properties, these powerful chemi-
cal agents are now routinely used to stabilize bone in
the management of metastatic bone disease [20,45,46].
As the RANK/RANKL/OPG signaling pathways are
critical for bone turnover, blocking either RANK/
RANKL signaling pathways by anti-RANKL neutralizing
monoclonal antibodies or by anti-RANK monoclonal
antibodies, or by direct application of recombinant
OPG-protein, may lead to inhibition of osteoclast
differentiation, maturation and functional activity,
resulting in suppression of osteoclast-mediated bone
resorption [30]. Indeed, a monoclonal antibody blocking
agent which binds to RANKL is already in use in treat-
ing metastatic bone disease [33,47].
Likewise agents that have the capacity to neutralize or
reduce the production of PTHrH, TGF-b or to block
the receptors of endothelin-A or TGF-b receptor 1
kinase, can inhibit the development and progression of
metastatic bone disease, and are currently under investi-
gation for clinical use [20,37,45].
Biochemical markers of bone formation
Biochemical markers of bone formation include bone-
specific alkaline phosphatase, osteocalcin and C- and N-
terminal propeptide of type 1 procollagen; and those of
bone resorption include hydroxyproline, pyridinoline,
deoxypyridoline, C- and N-terminal crosslinked telopep-
tide of type 1 collagen, and bone sialoprotein [48-52].
As bone metastases disrupt normal bone remodeling,
many biochemical markers of bone turnover are ele-
vated in patients with metastatic bone disease regardless
of whether the metastases are predominantly osteolytic
or osteoblastic [48-52]. With regard to bone formation
markers, the level of bone-specific alkaline phosphatase
is usually increased in advanced metastatic bone disease
reflecting active repair in an osteolytic lesion, or the pre-
sence of an osteoblastic lesion [51]. Of the bone resorp-
tion markers, N-telopeptide of type 1 collagen correlates
well with the presence and extent of bone metastases
and with the prognosis and response to treatment [49].
None of the biochemical markers of bone turnover
can monitor the development and progression of meta-
static bone disease as accurately as do well established
bone imaging techniques [53]. When used alone, they
do not possess sufficient diagnostic and prognostic spe-
cificity to assess the overall treatment outcome for
patients with cancer [50]. However, in combination with
other diagnostic techniques and prognostic markers, the
biochemical markers of bone turnover are useful tools
in the assessment cancer with metastatic bone disease
[48-53].
Metastases to the jaws
Metastases to bone frequently affect the long bones, ribs
and the vertebrae, but metastases to the jaws are
uncommon. Cancers from almost any primary site can
metastasize to the jaws, but those from the breast, lung,
kidney and prostate do so most frequently. Jaw metas-
tases occur with equal frequency in males and females;
the mandible is more often affected than the maxilla
[54-59]. In males, primary cancer of the lung most com-
monly metastasize to the jaws followed in frequency by
prostatic and renal cancers. In females, jaw metastasis
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lowed by primaries of the adrenal and genitalia [56].
Not infrequently a metastasis to the jaw is the first indi-
cation of the existence of an undiagnosed primary can-
cer [54-56].
It is not clear why the jaws are less affected by metas-
tases of osteotropic primary cancers than other bones.
However, it may be owing to the fact that the jaws are
not rich in hematopoetically active red bone marrow
where sinusoidal vascular spaces favour the establish-
ment of metastasis. Moreover breast cancer and prostate
cancer often occur in older people in whom the bone
marrow of the jaw is even more reduced [54]. It is prob-
able that the mandible is more affected by bone meta-
static growth than the maxilla because of the pattern of
its blood supply, and because the mandibular retromolar
area, the jaw site most affected by metastases, has more
red bone marrow than other jaw sites [60].
Summary
Metastasis of primary cancer cells to bone and subse-
quent metastatic bone growth is a complex process
regulated by multiple signalling pathways and character-
ized by molecular interactions between the metastatic
cells and the extracellular and cellular components of
the bone microenvironment. These interactions deter-
mine whether the metastatic bone disease will be predo-
minantly osteolytic or osteoblastic.
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